(Q24236550)

1

0 references

Nikesh Adunuri

2

0 references

Sudeep S. Gill

3

0 references

Andrea Gruneir

4

0 references

Nathan Herrmann

Cochrane Database of Systematic Reviews

5

0 references

publication date

16 February 2011

0 references

published in

0 references

cites work

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Regression to the mean: implications for clinical trials of psychotropic agents in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Sertraline treatment of elderly patients with depression and cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Citalopram for verbal agitation in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Fluvoxamine for psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

21 January 2018

Snoezelen for dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

A description of agitation in a nursing home

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Paroxetine-induced hyponatremia in older adults: a 12-week prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Antipsychotic drug use and mortality in older adults with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The role of norepinephrine in the behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Role of serotonin in the behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Haloperidol for agitation in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Trazodone for agitation in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Prevalence of dementia in the United States: the aging, demographics, and memory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Effect of selective serotonin reuptake inhibitors on the risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

A new rating scale for dementia syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

Minaprine for senile dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

A survey of Australian and New Zealand old age psychiatrists' preferred medications to treat behavioral and psychological symptoms of dementia (BPSD)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

Preliminary communication. A double-blind placebo-controlled trial of L-tryptophan to assess the degree of cognitive and behavioural improvement in patients with Alzheimer-type dementia and to compare differential response in clinical sub-groups.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

Double-blind trial of imipramine in Alzheimer's disease patients with and without depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008191.PUB2

7 January 2021